Involvement of Surfactant Protein D in Ebola Virus Infection Enhancement via Glycoprotein Interaction

Since the largest 2014–2016 Ebola virus disease outbreak in West Africa, understanding of Ebola virus infection has improved, notably the involvement of innate immune mediators. Amongst them, collectins are important players in the antiviral innate immune defense. A screening of Ebola glycoprotein (GP)-collectins interactions revealed the specific interaction of human surfactant protein D (hSP-D), a lectin expressed in lung and liver, two compartments where Ebola was found in vivo. Further analyses have demonstrated an involvement of hSP-D in the enhancement of virus infection in several in vitro models. Similar effects were observed for porcine SP-D (pSP-D). In addition, both hSP-D and pSP-D interacted with Reston virus (RESTV) GP and enhanced pseudoviral infection in pulmonary cells. Thus, our study reveals a novel partner of Ebola GP that may participate to enhance viral spread.

Download Full-text

Seroprevalence of Ebola virus infection in Bombali District, Sierra Leone

Journal of Public Health in Africa ◽

10.4081/jphia.2017.732 ◽

2017 ◽

Cited By ~ 5

Author(s):

Nadege Goumkwa Mafopa ◽

Gianluca Russo ◽

Raoul Emeric Guetiya Wadoum ◽

Emmanuel Iwerima ◽

Vincent Batwala ◽

...

Keyword(s):

Immune Response ◽

Virus Infection ◽

West Africa ◽

Sierra Leone ◽

Ebola Virus ◽

Virus Disease ◽

Asymptomatic Infection ◽

Ebola Virus Disease ◽

Efficient Immune Response ◽

Ebola Virus Infection

A serosurvey of anti-Ebola Zaire virus nucleoprotein IgG prevalence was carried out among Ebola virus disease survivors and their Community Contacts in Bombali District, Sierra Leone. Our data suggest that the specie of Ebola virus (Zaire) responsible of the 2013-2016 epidemic in West Africa may cause mild or asymptomatic infection in a proportion of cases, possibly due to an efficient immune response.

Download Full-text

Ebola Virus Ribonucleic Acid Detection in Semen More Than Two Years After Resolution of Acute Ebola Virus Infection

Open Forum Infectious Diseases ◽

10.1093/ofid/ofx155 ◽

2017 ◽

Vol 4 (3) ◽

Cited By ~ 21

Author(s):

William A Fischer ◽

Jerry Brown ◽

David Alain Wohl ◽

Amy James Loftis ◽

Sam Tozay ◽

...

Keyword(s):

Virus Infection ◽

Ribonucleic Acid ◽

Ebola Virus ◽

Infectious Virus ◽

Virus Disease ◽

Viral Rna ◽

Ebola Virus Disease ◽

Positive Specimen ◽

Ebola Virus Infection

Abstract Among 149 men who survived Ebola virus disease (EVD) and donated semen 260–1016 days after EVD onset, Ebola virus (EBOV) ribonucleic acid (RNA) was detected in 13 (9%). Of 137 men who donated semen 2 years after EVD onset, 11 (8%) had an EBOV RNA-positive specimen. The mechanism underlying the persistence of EBOV RNA in semen is unclear, and it is unclear whether the detection of viral RNA represents the presence of infectious virus.

Download Full-text

2P-0395 Surfactant protein D of the innate immune defense is negatively associated with obesity

Atherosclerosis Supplements ◽

10.1016/s1567-5688(03)90537-x ◽

2003 ◽

Vol 4 (2) ◽

pp. 125

Author(s):

U. Holmskov ◽

G. Lyster ◽

J. Hjelmborg ◽

R. Leth-Larsen ◽

V. Moeller ◽

...

Keyword(s):

Surfactant Protein ◽

Immune Defense ◽

Innate Immune ◽

Surfactant Protein D ◽

Negatively Associated ◽

Innate Immune Defense

Download Full-text

Surfactant protein D and bronchopulmonary dysplasia: a new way to approach an old problem

Respiratory Research ◽

10.1186/s12931-021-01738-4 ◽

2021 ◽

Vol 22 (1) ◽

Author(s):

Raquel Arroyo ◽

Paul S. Kingma

Keyword(s):

Immune Response ◽

Preterm Infants ◽

Bronchopulmonary Dysplasia ◽

Lung Tissue ◽

Lung Inflammation ◽

Tissue Injury ◽

Surfactant Protein ◽

Immune Defense ◽

Innate Immune ◽

Surfactant Protein D

AbstractSurfactant protein D (SP-D) is a collectin protein synthesized by alveolar type II cells in the lungs. SP-D participates in the innate immune defense of the lungs by helping to clear infectious pathogens and modulating the immune response. SP-D has shown an anti-inflammatory role by down-regulating the release of pro-inflammatory mediators in different signaling pathways such as the TLR4, decreasing the recruitment of inflammatory cells to the lung, and modulating the oxidative metabolism in the lungs. Recombinant human SP-D (rhSP-D) has been successfully produced mimicking the structure and functions of native SP-D. Several in vitro and in vivo experiments using different animal models have shown that treatment with rhSP-D reduces the lung inflammation originated by different insults, and that rhSP-D could be a potential treatment for bronchopulmonary dysplasia (BPD), a rare disease for which there is no effective therapy up to date. BPD is a complex disease in preterm infants whose incidence increases with decreasing gestational age at birth. Lung inflammation, which is caused by different prenatal and postnatal factors like infections, lung hyperoxia and mechanical ventilation, among others, is the key player in BPD. Exacerbated inflammation causes lung tissue injury that results in a deficient gas exchange in the lungs of preterm infants and frequently leads to long-term chronic lung dysfunction during childhood and adulthood. In addition, low SP-D levels and activity in the first days of life in preterm infants have been correlated with a worse pulmonary outcome in BPD. Thus, SP-D mediated functions in the innate immune response could be critical aspects of the pathogenesis in BPD and SP-D could inhibit lung tissue injury in this preterm population. Therefore, administration of rhSP-D has been proposed as promising therapy that could prevent BPD.

Download Full-text

A THEORETICAL STUDY ON FRACTIONAL EBOLA HEMORRHAGIC FEVER MODEL

Fractals ◽

10.1142/s0218348x22400321 ◽

2021 ◽

Author(s):

SHAHER MOMANI ◽

R. P. CHAUHAN ◽

SUNIL KUMAR ◽

SAMIR HADID

Keyword(s):

Virus Infection ◽

Ebola Virus ◽

Virus Disease ◽

Numerical Technique ◽

Disease Model ◽

Hemorrhagic Fever ◽

Health Concern ◽

Ebola Hemorrhagic Fever ◽

Conformable Derivatives ◽

Ebola Virus Infection

The Ebola virus infection (EVI), generally known as Ebola hemorrhagic fever, is a major health concern. The occasional outbreaks of virus occur primarily in certain parts of Africa. Many researches have been devoted to the study of the Ebola virus disease. In this paper, we have taken susceptible-infected-recovered-deceased-environment (SIRDP) system to investigate the dynamics of Ebola virus infection. We adopted fractional operators for a better illustration of model dynamics and memory effects. Initially, the Ebola disease model is modified with Caputo–Fabrizio arbitrary operator in Caputo sense (CFC) and we employed the fixed-point results for the existence and uniqueness of the solution of the fractional system. Further, we adopted the arbitrary fractional conformable and [Formula: see text]-conformable derivatives to the alternative representation of the model. For the numerical approximation of the system, we show a numerical technique based on the fundamental theorem of fractional calculus for CFC derivative and a numerical scheme called the Adams–Moulton for conformable derivatives. Finally, for the validation of theoretical results, the numerical simulations are displayed.

Download Full-text

Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection

F1000Research ◽

10.12688/f1000research.6110.1 ◽

2015 ◽

Vol 4 ◽

pp. 34 ◽

Cited By ~ 28

Author(s):

Veljko Veljkovic ◽

Philippe M. Loiseau ◽

Bruno Figadere ◽

Sanja Glisic ◽

Nevena Veljkovic ◽

...

Keyword(s):

Virtual Screening ◽

Virus Infection ◽

Ebola Virus ◽

Virus Disease ◽

Virtual Screen ◽

Experimental Drugs ◽

Theoretical Criterion ◽

Approved Drugs ◽

Molecular Libraries ◽

Ebola Virus Infection

The ongoing Ebola virus epidemic has presented numerous challenges with respect to control and treatment because there are no approved drugs or vaccines for the Ebola virus disease (EVD). Herein is proposed simple theoretical criterion for fast virtual screening of molecular libraries for candidate inhibitors of Ebola virus infection. We performed a repurposing screen of 6438 drugs from DrugBank using this criterion and selected 267 approved and 382 experimental drugs as candidates for treatment of EVD including 15 anti-malarial drugs and 32 antibiotics. An open source Web server allowing screening of molecular libraries for candidate drugs for treatment of EVD was also established.

Download Full-text